(101 days)
No
The document describes an electromechanical control unit and a sterile circuit for dialysis, with no mention of AI or ML technologies.
Yes
The device is indicated for the treatment of acute and chronic renal failure, or fluid overload, which are conditions requiring therapeutic intervention.
No
Explanation: The device description and intended use clearly state that the NxStage System One is for the "treatment" of renal failure or fluid overload using various dialysis methods. There is no mention of diagnosing any conditions.
No
The device description explicitly states it is comprised of a cycler (an electromechanical control unit) and a cartridge (a sterile, single-use extracorporeal blood and fluid management circuit), which are hardware components.
Based on the provided information, the NxStage System One is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use is for the treatment of renal failure and fluid overload using hemofiltration, hemodialysis, and/or ultrafiltration. These are therapeutic procedures performed directly on the patient's blood, not tests performed on samples outside the body to diagnose or monitor a condition.
- Device Description: The device description details an electromechanical control unit and a blood and fluid management circuit. This aligns with a system designed for extracorporeal blood treatment, not for analyzing biological samples.
- Lack of IVD Characteristics: The description does not mention any components or functions related to analyzing biological samples (like blood, urine, etc.) to provide diagnostic information. There's no mention of reagents, assays, or analytical measurements typically associated with IVDs.
Therefore, the NxStage System One is a therapeutic medical device used for blood purification, not an IVD.
N/A
Intended Use / Indications for Use
The NxStage System One is indicated for the treatment of acute and chronic renal failure, or fluid overload using hemofiltration, hemodialysis, and/or ultrafiltration, in an acute or chronic care facility.
The System is also indicated for home hemodialysis, including home nocturnal hemodialysis.
All treatments must be administered under physician's prescription, and must be performed by a trained and qualified person, considered to be competent in the use of this device by the prescribing physician.
Product codes
ODN
Device Description
The NxStage System One is comprised of the NxStage Cycler, an electromechanical control unit; the NxStage Cartridge, a sterile, single-use extracorporeal blood and fluid management circuit (with or without a preattached high permeability filter) that mounts integrally within the NxStage Cycler. The combined system is designed to deliver hemofiltration, hemodialysis and/or ultrafiltration in an acute or chronic care facility. The NxStage System One is also indicated for home hemodialysis, including home nocturnal hemodialysis.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
acute or chronic care facility.
home hemodialysis, including home nocturnal hemodialysis.
All treatments must be administered under physician's prescription, and must be performed by a trained and qualified person, considered to be competent in the use of this device by the prescribing physician.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The following non-clinical testing was conducted:
Simulated treatments
The following clinical testing was conducted:
No Clinical testing was conducted
Conclusion: Results of the non-clinical testing have documented that the proposed NxStage System One is substantially equivalent to the predicate device and is suitable for the labeled indications for use.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
K043436, K060296, K090919, K111174, K140571
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 876.5860 High permeability hemodialysis system.
(a)
Identification. A high permeability hemodialysis system is a device intended for use as an artificial kidney system for the treatment of patients with renal failure, fluid overload, or toxemic conditions by performing such therapies as hemodialysis, hemofiltration, hemoconcentration, and hemodiafiltration. Using a hemodialyzer with a semipermeable membrane that is more permeable to water than the semipermeable membrane of the conventional hemodialysis system (§ 876.5820), the high permeability hemodialysis system removes toxins or excess fluid from the patient's blood using the principles of convection (via a high ultrafiltration rate) and/or diffusion (via a concentration gradient in dialysate). During treatment, blood is circulated from the patient through the hemodialyzer's blood compartment, while the dialysate solution flows countercurrent through the dialysate compartment. In this process, toxins and/or fluid are transferred across the membrane from the blood to the dialysate compartment. The hemodialysis delivery machine controls and monitors the parameters related to this processing, including the rate at which blood and dialysate are pumped through the system, and the rate at which fluid is removed from the patient. The high permeability hemodialysis system consists of the following devices:(1) The hemodialyzer consists of a semipermeable membrane with an in vitro ultrafiltration coefficient (K
uf ) greater than 8 milliliters per hour per conventional millimeter of mercury, as measured with bovine or expired human blood, and is used with either an automated ultrafiltration controller or anther method of ultrafiltration control to prevent fluid imbalance.(2) The hemodialysis delivery machine is similar to the extracorporeal blood system and dialysate delivery system of the hemodialysis system and accessories (§ 876.5820), with the addition of an ultrafiltration controller and mechanisms that monitor and/or control such parameters as fluid balance, dialysate composition, and patient treatment parameters (e.g., blood pressure, hematocrit, urea, etc.).
(3) The high permeability hemodialysis system accessories include, but are not limited to, tubing lines and various treatment related monitors (e.g., dialysate pH, blood pressure, hematocrit, and blood recirculation monitors).
(b)
Classification. Class II. The special controls for this device are FDA's:(1) “Use of International Standard ISO 10993 ‘Biological Evaluation of Medical Device—Part I: Evaluation and Testing,’ ”
(2) “Guidance for the Content of 510(k)s for Conventional and High Permeability Hemodialyzers,”
(3) “Guidance for Industry and CDRH Reviewers on the Content of Premarket Notifications for Hemodialysis Delivery Systems,”
(4) “Guidance for the Content of Premarket Notifications for Water Purification Components and Systems for Hemodialysis,” and
(5) “Guidance for Hemodialyzer Reuse Labeling.”
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
June 4, 2015
NxStage Medical, Inc. Mary Lou Stroumbos Director, Regulatory Affairs 350 Merrimack Street Lawrence, MA 01843
Re: K150472
Trade/Device Name: NxStage System One Regulation Number: 21 CFR§ 876.5860 Regulation Name: High permeability hemodialysis system Regulatory Class: II Product Code: ODN Dated: May 4, 2015 Received: May 5, 2015
Dear Mary Lou Stroumbos,
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.
1
You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
for
Sincerely yours.
Image /page/1/Picture/6 description: The image shows the name "Herbert P. Lerner -S" in a bold, sans-serif font. The text is black against a white background. The letters are evenly spaced and the text is left-aligned.
Benjamin R. Fisher, Ph.D. Director Division of Reproductive, Gastro-Renal, and Urological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K150472
Device Name NxStage System One
Indications for Use (Describe)
The NxStage System One is indicated for the treatment of acute and chronic renal failure, or fluid overload using hemofiltration, hemodialysis, and/or ultrafiltration, in an acute or chronic care facility.
The System is also indicated for home hemodialysis, including home nocturnal hemodialysis.
All treatments must be administered under physician's prescription, and must be performed by a trained and qualified person, considered to be competent in the use of this device by the prescribing physician.
| Type of Use (Select one or both, as applicable) |
|---|
| ------------------------------------------------- |
X Prescription Use (Part 21 CFR 801 Subpart D)
_ Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
This 510(k) Summary is being submitted in accordance with the requirements of the Safe Medical Device Act (SMDA) of 1990. The content contained in this 510(k) summary has been provided in conformance with 21 CFR §807.92
| A. Date Prepared: | February 20, 2015 |
|---|---|
| B. Submitter's Information: | |
| Name: | NxStage Medical, Inc. |
| Address: | 350 Merrimack Street |
| Lawrence, MA 01843 | |
| FDA Establishment | |
| Owner/Operator | |
| Number: | 9045797 |
| Contact Person: | Mary Lou Stroumbos |
| Director, Regulatory Affairs | |
| Phone: | |
| Fax: | (978) 687-4872 |
| (978) 687-4750 | |
| Manufacturer: | NxStage Medical, Inc. |
| 350 Merrimack Street | |
| Lawrence, MA 01843 | |
| FDA Establishment | |
| Registration Number: | 3003464075 |
| Sterilization Site: | Steris Isomedix (NxStage Cartridge |
| Express) | |
| 1000 S. Sarah Place | |
| Ontario, CA 91761 |
4
NxStage Medical, Inc. NxStage System One 510(k) Premarket Notification
- C. Device Name: NxStage System One Trade/Proprietary Name: Common/Usual Name: Hemodialysis System Classification Name: High Permeability Hemodialysis System Requlation Number: 876.5860 Product Code: ODN Device Classification: Class II Device Panel: Gastroenterology/Urology
D. Substantial Equivalence:
The NxStage System One has the same intended use and utilizes the same fundamental technology as the predicate NxStage System One. The NxStage System One has been compared to the legally marketed predicate device as cleared through K141752 (December 19, 2014) and was found to be substantially equivalent.
E. Device Description/Indications for Use:
The NxStage System One is comprised of the NxStage Cycler, an electromechanical control unit; the NxStage Cartridge, a sterile, single-use extracorporeal blood and fluid management circuit (with or without a preattached high permeability filter) that mounts integrally within the NxStage Cycler. The combined system is designed to deliver hemofiltration, hemodialysis and/or ultrafiltration in an acute or chronic care facility. The NxStage System One is also indicated for home hemodialysis, including home nocturnal hemodialysis.
5
Indications for use:
The NxStage System One is indicated for the treatment of acute and chronic renal failure or fluid overload using hemofiltration, hemodialysis, and/or ultrafiltration, in an acute or chronic care facility.
The System is also indicated for home hemodialysis, including home nocturnal hemodialysis.
All treatments must be administered under physician's prescription, and must be performed by a trained and qualified person, considered to be competent in the use of this device by the prescribing physician.
F. Technological Characteristics:
The proposed device has the same technological characteristics and is identical in design and configuration as compared to the predicate device. The proposed device is designed with similar software, components and features also used in the predicate device.
| Table 1
| Device Technological Characteristics Comparison Table | ||
|---|---|---|
| Parameter | Proposed Device | |
| NxStage System One | Predicate Device | |
| NxStage System One | ||
| (K141752) | ||
| Intended Use | ||
| Hemodialysis | Yes | Yes |
| Hemofiltration | Yes | Yes |
| Ultrafiltration | Yes | Yes |
| Technology / Components: | ||
| Pumps | Same | 4 peristaltic pumps |
| Valves (clamps) | Same | 2 solenoid actuated pinch clamps |
| Same | 8 cam driven pinch clamps | |
| Air / fluid detectors | Same | 3 ultrasonic air/ fluid detectors |
| Blood leak detector | Same | 1 optical blood leak detector |
| Pressure transducers | Same | 5 electronic pressure transducers |
| Temperature sensors | Same | 1 electronic temperature sensor |
Special 510(k) Premarket Notification NxStage Medical, Inc.
6
NxStage Medical, Inc.
NxStage System One 510(k) Premarket Notification
| Table 1
| Device Technological Characteristics Comparison Table | ||||
|---|---|---|---|---|
| Parameter | Proposed Device | |||
| NxStage System One | Predicate Device | |||
| NxStage System One | ||||
| (K141752) | ||||
| Flow Rates: | ||||
| Blood | ||||
| Prescription Fluid /Dialysate | ||||
| Flow | ||||
| Ultrafiltration | ||||
| Transmembrane Pressure | Same | |||
| Same | ||||
| Same | ||||
| Same | 10-600 ml/min | |||
| 0-18000 ml/hr | ||||
| 0-2400 ml/hr | ||||
| Yes | ||||
| Monitoring Specification | ||||
| Venous Pressure Monitor | ||||
| Effluent fluid Pressure Monitor | ||||
| Air Detector | Same | |||
| Same | ||||
| Same | 0 to 400 mmHg | |||
| 0 to 500 mmHg | ||||
| Reduction of detector signal lasting 6 ms | ||||
| Blood Leak Detector | Same | minimum (Approximates a 60 micro liter | ||
| bubble at 400 mmHg venous pressure and | ||||
| 600 ml/min blood flow) | ||||
| 15% reduction in detector signal lasting 20 | ||||
| seconds minimum. Signal reduction % | ||||
| based on a 0.35 ml/min leak rate of 32 Hct | ||||
| blood. | ||||
| Effluent Volume Accuracy | Same | Greater of 300 ml/ 12 hr or 3% of exchange | ||
| volume (For software versions 4.7 and | ||||
| below) | ||||
| For software versions 4.8 and higher: | ||||
| Specification greater of | ||||
| Therapy | ||||
| Fluid Flow | ||||
| Rate L/hr) | ||||
| +100 |
3
ml/hr*
- 5% UF*
or - 25
≤ 3
ml/hr*
*Representing 95/90 tolerance interval
established under controlled laboratory
testing conditions. | | |
| IV Prescription Fluid | Same | Off-line, sterile- physician prescribed,
indicated for infusion | | |
| Dialysate | Same | Dialysate available as pre-packaged pre-
mixed sterile fluids or via the PureFlow SL
(K043436 K060296, K090919, K111174 &
K140571) | | |
| Compatible Blood Tubing Set | Same | NxStage Standard Cartridge | | |
| Software | Same | Software version 4.10 | | |
Special 510(k) Premarket Notification NxStage Medical, Inc.
7
Summary of Non-Clinical Test/Performance Testing - Bench and G. Clinical Testing
NxStage believes that the information and data provided in this submission clearly describes the proposed device and demonstrates that the device is adequately designed for the labeled indications for use. Performance, verification and validation testing was conducted to characterize performance of the proposed device and the predetermined acceptance criteria were met.
The following non-clinical testing was conducted:
Simulated treatments o
The following clinical testing was conducted:
No Clinical testing was conducted
Conclusion: Results of the non-clinical testing have documented that the proposed NxStage System One is substantially equivalent to the predicate device and is suitable for the labeled indications for use.